secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001551152-23-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q3 adj EPS $2.95 (down 19.4%); raises FY23 and FY24 guidance; dividend up 4.7%
--------------------------------------------------------------------------------

- Q3 GAAP diluted EPS $1.00 (down 54.8% YoY); adjusted diluted EPS $2.95 (down 19.4%); net rev $13.93B (down 6.0%).
- Immunology down 11.3% as Humira fell 36.2%; Skyrizi up 52.1% and Rinvoq up 59.8% drove growth in other segments.
- Raises 2023 adj EPS guidance to $11.19-$11.23 from $10.86-$11.06; 2024 floor raised to $11.00 from $10.70.
- Dividend increased 4.7% to $1.55/quarter; payable Feb 15, 2024 to holders of record Jan 16, 2024.
- Records $2.1B pre-tax impairment on Imbruvica intangible due to IRA price negotiation; remaining carrying value $1.8B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000040/0001551152-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000040/abbv-20231027.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer